HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

483.155

-13.603-2.74%

Number of Gainers:7

Number of Losers:23

Number of Flat:3

PE:- -

High:496.758

Open:496.758

Low:480.328

Close:496.758

Volume:115.32M

Turnover:2.61B

Market Cap:306.93B

Float Cap:273.30B

Loading ...

Ascletis Pharma FY26 H1 Net Loss More than Doubled to RMB 319.67 Million; Total Income Falls 48.9% to RMB 52.98 Million

Ascletis Pharma H1 Net Income Attributable RMB -319.671 Million

THOMSON REUTERS

China's Hongcheng Environmental Technology HY Revenue Rises on Higher Sulphuric Acid Prices

Alphamab Oncology Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at HKD 8.9 Each

CStone Plans First Wave of Global Phase III Trials for Cs2009 by End-2026

CStone Says Pralsetinib Sales Volume Jumps Nearly 500% After China NRDL Listing

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study

MT Newswires Live

Acotec Scientific FY26 H1 Swings to Net Loss of RMB 80.83 Million; Revenue Falls 5.6% to RMB 331.58 Million

Acotec Scientific - Hy Revenue RMB 331.6 Mln

THOMSON REUTERS

Acotec Scientific Holdings Limited - Board Does Recommend Payment of Interim Dividend

THOMSON REUTERS

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Repurchase for Cancellation

China's Angelalign H1 Revenue Rises on Higher Clear Aligner Case Volume

Israel's BioLineRx Q2 Net Loss Widens on Higher R&D Expenses

OCUMENSION-B's Dry Eye Candidate OT-202 Commences Late-Stage Dosing in China

Ocumension Completes First Patient Enrollment in Phase III China Trial of Dry Eye Drug OT-202

China's So-Young Q2 Revenue Rises, Net Loss Narrows

China's Rainmed Medical H1 Revenue Rises, Net Loss Narrows

Hong Kong's Lee's Pharmaceutical H1 Profit Jumps on Higher-Margin Product Sales

Lee's Pharm Reports 41.4% Profit Surge in H1 Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/BK1574/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":483.15506,"timestamp":1789114133774,"preClose":496.75812,"halted":0,"volume":115323363,"delay":0,"changeRate":-0.027384,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-13.603058,"latestTime":"09-11 16:00:00","open":496.75812,"high":496.75812,"low":480.32812,"amount":2611810568,"amplitude":0.033074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.703217,"peRate":164.740195,"turnoverRate":0.004215,"increases":6,"decrements":25,"flats":1,"marketCap":306930068880,"floatMarketCap":273297591592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.033074,"preClose":496.75812,"low":480.32812,"pbRate":"3.703217","latestPrice":483.15506,"volume":115323363,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.004215,"peRate":164.740195,"marketCap":306930068880,"floatMarketCap":273297591592,"timestamp":1789114133774,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":23,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663100571","title":"Ascletis Pharma FY26 H1 Net Loss More than Doubled to RMB 319.67 Million; Total Income Falls 48.9% to RMB 52.98 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663100571","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663100571?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:15","pubTimestamp":1788182109,"startTime":"0","endTime":"0","summary":"Ascletis Pharma FY26 H1 net loss more than doubled to RMB 319.67 million; total income falls 48.9% to RMB 52.98 millionAscletis Pharma posted a net loss of RMB 319.67 million, more than tripling year-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL7N2P2m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663800579","title":"Ascletis Pharma H1 Net Income Attributable RMB -319.671 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663800579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663800579?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:15","pubTimestamp":1788182101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nPLX1DNJ6W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","BK1515","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663053100","title":"China's Hongcheng Environmental Technology HY Revenue Rises on Higher Sulphuric Acid Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2663053100","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663053100?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:59","pubTimestamp":1788181171,"startTime":"0","endTime":"0","summary":"China's Hongcheng Environmental Technology HY revenue rises on higher sulphuric acid pricesOverviewChina environmental solutions provider's interim revenue rose 40% yr/yr for six months ended JuneGros","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0GW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","06699","BK1574","02297","BK1593","06609","02265","BK1100","BK1140","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003766","title":"Alphamab Oncology Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at HKD 8.9 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003766","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003766?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:46","pubTimestamp":1788180401,"startTime":"0","endTime":"0","summary":"Alphamab Oncology files HKEX next-day disclosure return reporting share repurchase at HKD 8.9 eachAlphamab Oncology repurchased 110,000 ordinary shares on HKEX on Aug. 31, 2026 for treasury.Buyback pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL3kwvC4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003801","title":"CStone Plans First Wave of Global Phase III Trials for Cs2009 by End-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003801","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003801?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:23","pubTimestamp":1788179038,"startTime":"0","endTime":"0","summary":"CStone plans first wave of global Phase III trials for CS2009 by end-2026CStone highlighted stronger mid-stage clinical results for lead cancer drug CS2009, supporting plans to start global Phase III ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLpMLV5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663038020","title":"CStone Says Pralsetinib Sales Volume Jumps Nearly 500% After China NRDL Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2663038020","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663038020?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:23","pubTimestamp":1788179035,"startTime":"0","endTime":"0","summary":"CStone says pralsetinib sales volume jumps nearly 500% after China NRDL listingCStone reported 2026 interim results, highlighting CS2009 Phase I/II updates through August with sustained safety and dee","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL1XJFFr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663600336","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2663600336","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663600336?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:23","pubTimestamp":1788178980,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy.-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU1223083913.SGD","LU1093756325.SGD","LU1721428933.USD","BK1574","IND","BK4107","XME","CDE","LU0053666078.USD","BK4121","IE00B5TLWC47.USD","BK4211","GDXJ","BK4017","LU0210528500.USD","LU0347712357.USD","LU1223082196.USD","ORR","SGDM","SIL","BK4585","BK4567","IE00BYQQ9H92.USD","IE00BFXG0V08.USD","PFS","LU2487616109.SGD","BK4195","BK4548","LU2413666699.HKD","LU1093756168.USD","L","02616","LU2211817866.USD","BK1161","BK4588","MTD","LU2413666426.HKD","LU1223082519.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008151","title":"Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008151","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008151?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:04","pubTimestamp":1788177853,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics (HKG:1477) enrolled the first patient in a phase III clinical trial of OT-202.The trial is studying the drug for the treatment of dry eye disease in China, according to a Monday Hong Kong bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK4539","LENZ","BK4139","01477","BK4007","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663307706","title":"Acotec Scientific FY26 H1 Swings to Net Loss of RMB 80.83 Million; Revenue Falls 5.6% to RMB 331.58 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663307706","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663307706?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:21","pubTimestamp":1788175287,"startTime":"0","endTime":"0","summary":"Acotec Scientific FY26 H1 swings to net loss of RMB 80.83 million; revenue falls 5.6% to RMB 331.58 millionAcotec Scientific posted an IFRS net loss of RMB 80.83 million, swinging from profit; basic E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL8vjVj7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0138981039.USD","LU0823417737.USD","LU2324357040.USD","LU1718418525.SGD","LU0251132253.USD","LU1791710400.SGD","SGXZ57979304.SGD","LU2362541513.USD","BK1587","LU0345769631.USD","LU2506952170.USD","LU0353189763.USD","BSX","LU2242649171.HKD","LU0345769128.USD","LU2362541273.HKD","IE00BFTCPJ56.SGD","LU0823416689.USD","LU1989772923.USD","SG9999001176.USD","LU0823417653.USD","IE00BJJMRZ35.SGD","LU0432979614.USD","LU1061106388.HKD","LU1989772840.SGD","LU1989771016.USD","LU2265009873.SGD","LU1989764664.SGD","BK1100","LU0882574055.USD","BK1574","LU1023059063.AUD","SG9999001176.SGD","LU2506952097.USD","LU0225283273.USD","06669","LU0353189680.USD","LU0950375773.USD","LU2357305700.SGD","LU0122379950.USD","LU2244417387.USD","LU2491049909.HKD","IE00BJT1NW94.SGD","IE0002141913.USD","LU1720051108.HKD","IE00B4R5TH58.HKD","LU2491050154.USD","LU1057294990.SGD","LU1366192091.USD","LU2506951875.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077780","title":"Acotec Scientific - Hy Revenue RMB 331.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077780?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:20","pubTimestamp":1788175256,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06669","BK1574","BK1100","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077039","title":"Acotec Scientific Holdings Limited - Board Does Recommend Payment of Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077039?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:20","pubTimestamp":1788175256,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0BK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1100","BK1574","06669"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077197","title":"Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Repurchase for Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077197","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077197?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:14","pubTimestamp":1788174854,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge files HKEX next-day disclosure return on share repurchase for cancellationZylox-Tonbridge bought back 53,000 H shares on Aug. 31, holding them as treasury shares; no shares were cancel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL5gftGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02190","BK1100","BK1587","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077162","title":"China's Angelalign H1 Revenue Rises on Higher Clear Aligner Case Volume","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077162","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077162?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:13","pubTimestamp":1788174790,"startTime":"0","endTime":"0","summary":"China's Angelalign H1 revenue rises on higher clear aligner case volumeOverviewChina clear aligner maker's H1 2026 revenue rose 42.9% yr/yrAdjusted net profit for H1 2026 grew 79.5% yr/yrCompany attri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","06699","06622","BK1191","BK1587","BK1574","BK1100","BK1583","01477","06609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663686077","title":"Israel's BioLineRx Q2 Net Loss Widens on Higher R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2663686077","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663686077?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:09","pubTimestamp":1788174543,"startTime":"0","endTime":"0","summary":"Israel's BioLineRx Q2 net loss widens on higher R&DexpensesOverviewIsrael biopharma's Q2 revenue was flat yr/yr at $0.3 mlnNet loss widened to $4.3 mln from $3.9 mln on higher R&D and admin expensesCo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BLRX","BK1191","01477","01228","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131581918","title":"OCUMENSION-B's Dry Eye Candidate OT-202 Commences Late-Stage Dosing in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1131581918","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131581918?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:28","pubTimestamp":1788172096,"startTime":"0","endTime":"0","summary":"OCUMENSION-B (01477) has announced that the first patient has been enrolled in the Chinese Phase III clinical trial for OT-202, its investigational therapy for dry eye disease (DED). This milestone...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","BK1191","PSYK","BK1574","BMED","IBBJ","01477","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663074131","title":"Ocumension Completes First Patient Enrollment in Phase III China Trial of Dry Eye Drug OT-202","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074131","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663074131?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:25","pubTimestamp":1788171922,"startTime":"0","endTime":"0","summary":"Ocumension completes first patient enrollment in Phase III China trial of dry eye drug OT-202Ocumension Therapeutics completed first patient enrollment in a China Phase III trial of OT-202 for moderat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL64Bjf6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663878074","title":"China's So-Young Q2 Revenue Rises, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2663878074","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663878074?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:11","pubTimestamp":1788171110,"startTime":"0","endTime":"0","summary":"China's So-Young Q2 revenue rises, net loss narrowsOverviewChina aesthetic treatment platform's Q2 revenue rose 33% yr/yr, driven by branded center expansionNet loss for Q2 narrowed yr/yr, reflecting ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK1574","06609","BK1587","SY","BK4077","BK4503","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071777","title":"China's Rainmed Medical H1 Revenue Rises, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071777","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663071777?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:08","pubTimestamp":1788170928,"startTime":"0","endTime":"0","summary":"China's Rainmed Medical H1 revenue rises, net loss narrowsOverviewChina medical device maker's H1 revenue rose 41% yr/yr, driven by caFFR system salesNet loss attributable to shareholders narrowed to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0BA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","06609","BK1191","01228","BK1587","BK1100","01477","02297"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663437071","title":"Hong Kong's Lee's Pharmaceutical H1 Profit Jumps on Higher-Margin Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2663437071","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663437071?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:00","pubTimestamp":1788170409,"startTime":"0","endTime":"0","summary":"Hong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product salesOverviewHong Kong pharma maker's interim revenue grew 14.6% yr/yr for six months ended June 2026Net income attributable t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0AP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1583","BK1515","06622","01477","BK1587","00570","BK1191","BK1574","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121505356","title":"Lee's Pharm Reports 41.4% Profit Surge in H1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1121505356","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121505356?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:54","pubTimestamp":1788170056,"startTime":"0","endTime":"0","summary":"LEE'S PHARM (00950) has announced its interim results for 2026, posting a revenue of approximately HK$797 million, marking a year-on-year increase of 14.6%.The company recorded a profit attributable...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950","BK1191","06622","BK1587","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":11,"totalSize":259,"code":"91000000","status":"200"}]}}